12th Alzheimer's and Parkinson's Drug Development Summit

Kongressthemen
After a 17-year hiatus in drug approvals for neurodegeneration, disease-modifying drugs for AD have finally broken the ice. With Lecanemab's clinically proven 30% reduction in cognitive decline receiving the green light from the FDA and PMDA and Eli Lilly's Donanemab hot on their heels for approval, 58 new trials entering the pipeline this year, and the alpha-synuclein self-seeding assay changing the game for PD drug development.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
Brochure: https://go.evvnt.com/2146026-3?pid=4832

Speakers: Achim Kless, PhD, Senior Director Pain Genetics, Eli Lilly and Co., Arnon Rosenthal, Co-Founder and Chief Executive Officer, Alector Pharmaceuticals LLC, and more

https://go.evvnt.com/2146026-2?pid=4832

Frau Erin Thomas